Financing

Debt Repayments

Eli Lilly Debt Repayments decreased by 3.6% to $750.00M in Q1 2026 compared to the prior quarter. Over 2 years (FY 2021 to FY 2024), Debt Repayments shows a downward trend with a -41.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryLeverage
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026

How to read this metric

A decrease may indicate a focus on capital preservation or refinancing, while a significant increase signals active debt reduction or maturity fulfillment.

Detailed definition

Represents the total cash outflows used to reduce the principal balance of short-term and long-term debt obligations. Th...

Peer comparison

Standard across all capital-intensive industries; peers with high leverage typically show higher repayment activity.

Metric ID: debt_repayment

Historical Data

16 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q1 '26
Value$0.00$1.91B$100.00K$710.10M$849.90M$0.00$0.00$0.00$0.00$166.00M$166.00M$166.00M$166.00M$0.00$778.10M$750.00M
QoQ Change-100.0%>999%+19.7%-100.0%+0.0%+0.0%+0.0%-100.0%-3.6%
YoY Change-100.0%-100.0%-100.0%+368.7%
Range$0.00$1.91B
Avg YoY Growth+17.2%
Median YoY Growth-100.0%

Frequently Asked Questions

What is Eli Lilly's debt repayments?
Eli Lilly (LLY) reported debt repayments of $750.00M in Q1 2026.
What is the long-term trend for Eli Lilly's debt repayments?
Over 2 years (2021 to 2024), Eli Lilly's debt repayments has grown at a -41.0% compound annual growth rate (CAGR), from $1.91B to $664.00M.
What does debt repayments mean?
The total amount of cash used to pay down debt principal.